Lampalizumab

Antigen Binding Fragment (Fab) Monoclonal AntibodyRx: ResearchCompound: Investigational

Also known as: Anti-CFD Fab, Anti-factor D, FCFD4514S, RG7417

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

Lampalizumab is an anti-complement factor D Fab antibody fragment developed by Roche/Genentech for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Despite promising Phase II (MAHALO) results, two pivotal Phase III trials (CHROMA and SPECTRI) failed to meet their primary endpoints, and the development program was discontinued in 2018.

Mechanism of Action

Inhibits complement factor D (CFD), a serine protease required for activation of the alternative complement pathway, thereby reducing complement-mediated retinal pigment epithelium damage in geographic atrophy.

Routes of Administration

Intravitreal

Goals & Uses

  • Visual acuity preservation in geographic atrophyFunctional OutcomesLow
  • Reduction of geographic atrophy lesion growthOphthalmology / Retinal DiseaseLow
  • Complement pathway inhibition in AMDMechanistic / PharmacologicalModerate

Contraindications

  • Active intraocular inflammationInflammatoryModerate
  • Hypersensitivity to lampalizumab or any excipientImmunologicHigh
  • Ocular or periocular infectionInfectiousHigh

Adverse Effects

  • Increased intraocular pressureOcularCommon
  • Retinal detachmentOcularRare
  • Conjunctival hemorrhageOcularCommon
  • Vitreous floatersOcularCommon
  • EndophthalmitisOcular / InfectiousRare
  • Susceptibility to encapsulated bacterial infectionsImmunologic / InfectiousUnknown

Drug Interactions

  • Other complement inhibitorsModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Pediatric patientsAgeRelative
  • Patients with systemic complement deficienciesImmunologicRelative

Regulatory Status

  • European UnionInvestigationalNo marketing authorization application filed; program discontinued after Phase III trial failures.
  • United StatesInvestigationalDevelopment discontinued by Genentech/Roche in 2018 after Phase III failure; no NDA submitted.
  • United KingdomInvestigationalNo approval; program discontinued globally in 2018.

No regulatory approval granted in any jurisdiction. Phase III trials (CHROMA and SPECTRI) failed to demonstrate significant reduction in GA lesion growth vs. sham; Roche discontinued clinical development in 2018.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack